Abstract
Aim There is increasing evidence that high expression levels of the gastric carcinoma highly expressed transcript 1 (GHET1), a long noncoding RNA (lncRNA), are associated with cancer prognosis and may be used as a valuable biomarker for cancer patients. The purpose of this meta-analysis was to analyze existing data to reveal potential clinical applications of GHET1 for cancer prognosis and tumor progression. All of these studies included in this meta-analysis were collected through a variety of retrieval strategies; and the enrolled articles were qualified via the meta-analysis of enrolled studies in epidemiology (MOOSE) and the preferred reporting items for systematic reviews and meta-analyses (PRISMA) checklists. Materials and Methods The literature collection was performed by a comprehensive search through electronic databases for studies published on or before March 10, 2019. These included the Cochrane library, PubMed, Embase, Web of Science, Springer, Science Direct, and three Chinese databases: CNKI, Weipu, and Wanfang. Seven studies that met the specified criteria were analyzed in the present research. Results The combined results indicate that an elevated GHET1 expression level is significantly associated with poor overall survival (OS) (HR = 2.40, 95% CI: 1.87–3.08, p < 0.001) and tumor progression (III/IV vs. I/II: HR = 1.80, 95% CI: 1.48–2.18, p < 0.001) in multiple cancers. The elevated GHET1 expression was also associated with lymph node metastasis (LNM) (HR = 2.44, 95% CI: 1.86–3.20, p < 0.001) in Chinese cancer patients. Conclusions. The present findings indicate that an increased GHET1 expression level is associated with poor OS, tumor progression, and LNM in patients with multiple tumors and may serve as a useful prognostic biomarker in Chinese cancer patients.
Highlights
Cancer is a major threat to human health over the world, with an ever increasing prevalence rate [1, 2]
The present findings indicate that an increased gastric carcinoma highly expressed transcript 1 (GHET1) expression level is associated with poor overall survival (OS), tumor progression, and lymph node metastasis (LNM) in patients with multiple tumors and may serve as a useful prognostic biomarker in Chinese cancer patients
We revealed that elevated GHET1 expression was predictive of high risk of LNM (HR = 2:44, 95% confidence intervals (CIs): 1.86–3.20, p < 0:001)
Summary
Cancer is a major threat to human health over the world, with an ever increasing prevalence rate [1, 2]. The molecular mechanisms underlying oncogenesis and tumor progression are still not fully elucidated; and this, in turn, restricts the prognostics for cancer patients. As a class of endogenous noncoding RNA, long noncoding RNA (lncRNA) has a broad range of molecular and cellular functions, including chromatin modification, gene imprinting, alternative splicing, dosage compensation, nuclear-cytoplasmic trafficking, and inactivation of major tumor suppressor genes [3,4,5]. Repeated findings suggest that lncRNAs may participate in a wide range of biological pathways with underlying oncogenesis and progression [8]. LncRNAs have attracted considerable attention as a class of Disease Markers modulators and may serve as potential biomarkers for cancer patients [9,10,11,12]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
